Tuberculosis and Lung Diseases

Aims & Scope

The Journal is aimed for professional development of researchers, doctors, teachers of medical universities and training institutions.

The Journal focuses on the presentation of results of research, case studies, issues of differential diagnostics and treatment in the phthisiologist’s practice, national programs on tuberculosis control in the Russian Federation, WHO strategies, discussion of prevention issues to stop transmission of TB/HIVco-infection, and extrapulmonary tuberculosis.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal does not charge a mandatory Article Processing Charge (APC). However, optional open access publication may incur fees based on the publisher’s policies.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• TB SITUATION IN RUSSIA

  Citation: 75

  Authors: O. B.

• Tuberculosis Situation in the Years of the COVID-19 Pandemic – 2020-2021

  Citation: 65

  Authors: I. A., V. V., S. A.

• INCIDENCE, MORTALITY AND PREVALENCE AS INDICATORS OF TUBERCULOSIS BURDEN IN WHO REGIONS , COUN TRIES OF THE WORLD AND THE RUSSIAN FEDERATION. Part 2. Tuberculosis mortality

  Citation: 54

  Authors: I. A., Evgeny M., S. E., S. A.

• SOCIALLY IMPORTANT INFECTIOUS DISEASES POSING A BIOLOGICAL THREAT TO THE POPULATION OF RUSSIA

  Citation: 38

  Authors: O. B.

• The multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis

  Citation: 37

  Authors: N. V., I. G., E. M., А. I., N. P., D. А.

• EXPERIENCE OF TREATMENT OF MULTIPLE DRUG RESISTANT TUBERCULOSIS PATIENTS WITH BEDAQUILINE IN AMUR REGION

  Citation: 33

  Authors: L. Yu., V. V., I. A., A. M., M. A., D. A.

• EXPERIENCE OF TREATING EXTENSIVE DRUG RESISTANT TUBERCULOSIS PATIENTS INCLUDING CONTINUOUS USE OF BEDAQUILINE, IN TOMSK REGION: IMMEDIATE AND POSTPONED RESULTS

  Citation: 33

  Authors: P. N., E. А., S. P., T. I., D. А.

• EFFICIENCY AND SAFETY OF CHEMOTHERAPY REGIMEN WITH SQ109 IN THOSE SUFFERING FROM MULTIPLE DRUG RESISTANT TUBERCULOSIS

  Citation: 33

  Authors: S. E., E. M., G. V., E. V., A. O., S. N., O. B., A. M., I. A.

• END TB – THE NEW WHO STRATEGY IN THE SDG ERA AND THE CONTRIBUTIONS FROM THE RUSSIAN FEDERATION

  Citation: 31

  Authors: M. C.

• Biomarkers and immunological tests. Experimental and clinical parallels of latent tuberculosis infection

  Citation: 31

  Authors: D. A.